Modulatory effects of TGF-β1 and BMP6 on thecal angiogenesis and steroidogenesis in the bovine ovary by Mattar, D. et al.
Modulatory effects of TGF- 1  and BMP6 β
on thecal angiogenesis and 
steroidogenesis in the bovine ovary 
Article 
Accepted Version 
Mattar, D., Samir, M., Laird, M. and Knight, P. G. (2020) 
Modulatory effects of TGF- 1  and BMP6 on thecal β
angiogenesis and steroidogenesis in the bovine ovary. 
Reproduction, 159 (4). pp. 397-408. ISSN 1470-1626 doi: 
https://doi.org/10.1530/REP-19-0311 Available at 
http://centaur.reading.ac.uk/88618/ 
It is advisable to refer to the publisher’s version if you intend to cite from the 
work.  See Guidance on citing .
To link to this article DOI: http://dx.doi.org/10.1530/REP-19-0311 
Publisher: BiScientifica 
All outputs in CentAUR are protected by Intellectual Property Rights law, 
including copyright law. Copyright and IPR is retained by the creators or other 
copyright holders. Terms and conditions for use of this material are defined in 
the End User Agreement . 
www.reading.ac.uk/centaur 
CentAUR 
Central Archive at the University of Reading 
Reading’s research outputs online
	 1	
Modulatory effects of TGF-β1 and BMP6 on thecal 1	
angiogenesis and steroidogenesis in the bovine ovary 2	
	3	
 4	
Dareen Mattar, Moafaq Samir, Mhairi Laird, Phil G Knight 5	
School of Biological Sciences, University of Reading, Whiteknights, Reading RG6 6	
6UB, UK 7	
 8	
MS is now at College of Veterinary Medicine, University of Wasit, Wasit, Iraq 9	
 10	
 11	











Angiogenesis plays an integral role in follicular and luteal development and is 22	
positively regulated by several intra-ovarian factors including vascular endothelial 23	
growth factor A (VEGFA) and fibroblast growth factor 2 (FGF2). Various 24	
transforming growth factor-β (TGF-β) superfamily members function as intra-ovarian 25	
regulators of follicle and luteal function but their potential roles in modulating ovarian 26	
angiogenesis have received little attention. In this study, we used a bovine theca 27	
interna culture model (exhibiting characteristics of luteinization) to examine the 28	
effects of TGF-β1 and bone morphogenetic protein 6 (BMP6) on angiogenesis and 29	
steroidogenesis. VEGFA/FGF2 treatment promoted endothelial cell network 30	
formation but had little or no effect on progesterone and androstenedione secretion or 31	
expression of key steroidogenesis-related genes. TGF-β1 suppressed basal and 32	
VEGFA/FGF2-induced endothelial cell network formation and progesterone secretion, 33	
effects that were reversed by an activin receptor-like kinase 5 (ALK5) inhibitor (SB-34	
431542). The ALK5 inhibitor alone raised androstenedione secretion and expression 35	
of several transcripts including CYP17A1. BMP6 also suppressed endothelial cell 36	
network formation under VEGFA/FGF2-stimulated conditions and inhibited 37	
progesterone secretion and expression of several steroidogenesis-related genes under 38	
basal and VEGFA/FGF2-stimulated conditions. These effects were reversed by an 39	
ALK1/2 inhibitor (K02288). Moreover, the ALK1/2 inhibitor alone augmented 40	
endothelial network formation, progesterone secretion, androstenedione secretion and 41	
expression of several steroidogenesis-related genes. The results indicate dual 42	
suppressive actions of both TGF-β1 and BMP6 on follicular angiogenesis and 43	
steroidogenesis. Further experiments are needed to unravel the complex interactions 44	
between TGF-β superfamily signalling and other regulatory factors controlling 45	





In contrast to most tissues and organs in adult organisms, the ovary is a highly 50	
dynamic organ displaying considerable tissue turnover and remodelling associated 51	
with recurrent growth and regression of follicles and corpora lutea (CL) throughout 52	
the reproductive lifespan of the female (Smith et al. 1999, Curry & Osteen 2003). 53	
Coordinated endocrine, paracrine and autocrine signals contribute to the regulation of 54	
follicle and CL turnover. These signals influence a number of physiological processes 55	
in the ovary including somatic cell proliferation, cyto-differentiation and apoptosis, 56	
oocyte maturation, steroidogenesis and angiogenesis.  57	
Angiogenesis plays an indispensible role in follicle and CL development and is a 58	
highly regulated process under the influence of both pro- and anti-angiogenic factors 59	
(Gerhardt & Betsholtz 2003, Robinson et al. 2009). Key pro-angiogenic factors 60	
expressed in the ovary include vascular endothelial growth factor A (VEGFA) and 61	
fibroblast growth factor 2, while anti-angiogenic factors include thrombospondins and 62	
angiostatin (Berisha et al. 2000, Berisha et al. 2004, Abramovich et al. 2009, 63	
Robinson et al. 2009, Woad & Robinson 2016). Follicular angiogenesis commences 64	
at the preantral stage with the theca layer acquiring a sheath of capillaries by the late 65	
secondary follicle stage; these capillaries do not penetrate the basal lamina and so the 66	
inner granulosa layer remains avascular until the peri-ovulatory period (Wulff et al. 67	
2001). Continued follicular growth up to the pre-ovulatory stage is accompanied by 68	
further development of the thecal capillary network whereas a decrease in vascularity 69	
occurs in atretic follicles (Jiang et al. 2003). After ovulation, the remnants of the 70	
ruptured follicle undergo transformation into the CL and this is accompanied by a 71	
further highly intense phase of angiogenesis, particularly in the early luteal phase 72	
when a high proportion of the proliferating cells in the CL are of vascular origin 73	
(Jiang et al. 2003). The follicular basal lamina breaks down and capillaries from the 74	
theca interna layer penetrate the previously avascular granulosa layer.  75	
Expression of the pro-angiogenic factors VEGFA and FGF2 is evident in granulosa 76	
and theca interna layers of bovine follicles from the secondary stage onwards with 77	
expression increasing through antral follicle stages (Berisha et al. 2000, Yang & 78	
Fortune 2007, Berisha et al. 2016). FGF2, FGF receptor (FGFR) and VEGF receptor 79	
(VEGFR1/2) mRNA and protein are more abundant in the theca interna than 80	
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granulosa layer of large bovine antral follicles (Berisha et al. 2000, Berisha et al. 81	
2016). The crucial role of VEGFA in driving ovarian angiogenesis is evidenced by the 82	
profound inhibition of both follicular (thecal) and luteal angiogenesis observed in 83	
marmosets treated with a ‘decoy receptor’ VEGF antagonist (Wulff et al. 2001, Wulff 84	
et al. 2002). Immunoneutralization of VEGF and FGF2 have also been shown to 85	
compromise bovine CL function (Yamashita et al. 2008, Woad et al. 2012). VEGF 86	
and FGF2 promote endothelial cell migration and proliferation, acting in a synergistic 87	
manner.  88	
Various transforming growth factor-β (TGF-β) superfamily members, including TGF-89	
β itself and several bone morphogenetic proteins (BMP) are expressed in the ovary 90	
and have been firmly implicated as autocrine/paracrine factors regulating different 91	
aspects of follicle and CL development, including cell proliferation/survival, 92	
differentiation and steroidogenesis (Erickson & Shimasaki 2003, Shimasaki et al. 93	
2004, Knight & Glister 2006). Thus far, their potential involvement in the regulation 94	
of angiogenesis in the ovary has received little attention with only one report, to our 95	
knowledge, documenting an inhibitory action of TGF-β1 on bovine luteal endothelial 96	
cell function and capillary morphogenesis (Maroni & Davis 2011). Since the uterine 97	
luteolytic signal PGF2α upregulates luteal expression of TGF-β the authors propose a 98	
role for TGF-β in the luteolytic mechanism in ruminants (Maroni & Davis 2011). In 99	
contrast, a stimulatory role for TGF-β1 in follicular angiogenesis was indicated by its 100	
ability to enhance secretion of pro-angiogenic factors, including VEGFA, by rat 101	
granulosa cells (Kuo et al. 2011). Also, BMP7 was found to upregulate VEGFA 102	
expression by human granulosa-lutein cells suggesting a positive role in 103	
follicular/luteal angiogenesis (Akiyama et al. 2014) 104	
TGF-β1 and TGF-β2 mRNAs are expressed by sheep ovarian thecal, stromal and 105	
vascular cells; vascular cells also expressed TGF-β3 mRNA (Juengel et al. 2004). 106	
Signalling receptors for TGF-β (TGFBR1 and TGFBR2) are expressed by the above 107	
cell-types as well as by granulosa cells (Juengel & McNatty 2005) indicative of 108	
intrafollicular autocrine/paracrine signalling. Likewise, several BMPs are expressed at 109	
the intraovarian level, together with their signallling receptors and extracellular 110	
binding proteins (Erickson & Shimasaki 2003, Glister et al. 2010). Apart from the 111	
aforementioned report of BMP7-induced upregulation of granulosal VEGFA 112	
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expression (Akiyama et al. 2014) we are not aware of any other studies examining the 113	
involvement of BMPs in follicular or luteal angiogenesis.  114	
Despite this, TGF-β and BMPs have been implicated in the regulation of endothelial 115	
cell function and angiogenesis in other tissues during normal development and in 116	
pathological conditions such as cardiovascular disease and cancer (Cai et al. 2012, 117	
Peshavariya et al. 2014, Guerrero & McCarty 2017). For instance, TGF-β has been 118	
shown to exert both pro- and anti-angiogenic actions, in a concentration and cell 119	
context-related manner (Orlova et al. 2011). Targeted deletion of TGF-β pathway 120	
components in mice is embryonically lethal due to disrupted angiogenesis and 121	
vasculogenesis (Goumans et al. 2009). Microvascular defects associated with 122	
hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension are linked 123	
to perturbations in TGF-β/BMP signalling (Cai et al. 2012, Guerrero & McCarty 124	
2017). Likewise, BMP2, BMP4, BMP6, BMP7 and BMP9 have been shown to induce 125	
angiogenesis in various in vitro models such as human or bovine aortic endothelial 126	
cells (BAEC) or human umbilical vein endothelial cells (HUVEC)  (David et al. 127	
2009). Several BMPs have been shown to enhance angiogenesis by upregulating 128	
VEGF expression (Deckers et al. 2002, He & Chen 2005). On the other hand, BMP9 129	
was shown to inhibit VEGF-induced angiogenesis in BAECs (Scharpfenecker et al. 130	
2007) while in a HUVEC culture model BMP4 exerted an anti-angiogenic action that 131	
was blocked by the BMP antagonist, chordin-like 1 (Kane et al. 2008). 132	
Given the paucity of information on the involvement of TGF-β superfamily signalling 133	
in follicular angiogenesis, in the present study we utlilized a bovine theca interna 134	
culture model to investigate the effects of two TGF-β superfamily ligands, TGF-β1 135	
and BMP6, alone and in combination with selective ALK5 and ALK1/2 inhibitors 136	
respectively, on follicular angiogenesis and steroidogenesis. The effects of the ALK 137	
inhibitors alone were also examined to seek evidence that endogenous TGFβ/BMP 138	
ligands modulate angiogenesis and steroidogenesis. Angiogenesis was evaluated by 139	
immunohistological analysis of endothelial cell network formation while 140	
steroidogenesis was evaluated by measuring steroid secretion (progesterone and 141	




Material and methods  145	
 146	
Bovine ovaries and collection of theca interna layers 147	
Ovaries from randomly cycling cattle were obtained from a local abattoir and 148	
transported to the laboratory in medium-199 supplemented with 1% (v/v) antibiotic 149	
antimycotic solution. Theca interna layers were recovered from 4-8mm diameter 150	
antral follicles and dissociated into single cells using collagenase digestion as 151	
described in detail elsewhere (Glister et al. 2005). 152	
	153	
Follicular angiogenesis cell culture model 154	
An in vitro follicular angiogenesis system, which utilizes primary cells derived from 155	
the theca interna, was adapted from the method developed by Robinson et al 156	
(Robinson et al. 2008) for bovine early CL tissue. In this system, tubule-like 157	
structures are produced and after seven days in culture, a network of endothelial cells 158	
has developed, which resembles a capillary bed.  159	
Briefly, sterile coverslips (circular, 19mm diameter x 0.25mm thick; Thermo 160	
Scientific, Rochester, NY) were transferred to wells of a 24-well plate (Nunclon, Life 161	
Technologies Ltd, Paisley, UK). One ml of gelatin-based Attachment Factor 1X 162	
(Thermo Fisher S006100) was added to each well and incubated at 38.5℃ with 163	
saturating humidity in 5% CO2 in air until used. Theca interna cells were seeded onto 164	
the coated coverslips at a density of 1 x 105/ml and cultured for 7 days. The medium 165	
used for the first day of culture was supplemented with 2% (v/v) fetal calf serum. This 166	
medium consisted of EBM-2 endothelial cell basal medium (500ml; Lonza, CC-4176), 167	
supplemented with undefined (proprietary) concentration of hydrocortisone (Lonza, 168	
CC-4112A), R3-insulin like growth factor-1 (Lonza, CC-4115A), ascorbic acid 169	
(Lonza CC-4116A), human epidermal growth factor (Lonza CC-4317A), antibiotics 170	
(GA-1000) (Lonza CC-4381) and heparin (CC-4396A). In-house supplements 171	
including apo-transferrin 5µg/ml (Sigma, T-2036) and sodium selenite 5ng/ml (Sigma, 172	
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S-9133), insulin 10ng/ml (bovine pancreas, Sigma, I-1882) and BSA 0.1% (Sigma, A-173	
9418) were also added. After the first day of culture, medium was removed and cells 174	
were washed with 1ml PBS. Thereafter cells were maintained in serum-free medium 175	
for the remainder of the culture period. Medium was changed and treatments applied 176	
on day 1, 3 and 5. On day 7 media were either discarded or retained for hormone 177	
assay; coverslips with adherent cells were either washed and fixed for subsequent 178	
immuno-staining of endothelial cells or lysed using RNeasy lysis buffer (Qiagen) for 179	
subsequent isolation of total RNA.  180	
 181	
Cell culture treatments 182	
Recombinant bovine FGF2 and VEGFA (R&D systems) were initially dissolved in 183	
sterile PBS containing 0.1% bovine serum albumin and 4 mM HCl. Cells were treated 184	
with/without these established angiogenic factors at final concentrations of 1 or 10 185	
ng/ml as used previously in a bovine luteal cell angiogenesis model (Robinson et al., 186	
2008). Recombinant human TGF-β1 (R&D systems) was dissolved in 4mM HCl to 187	
give a stock concentration of 10µg/ml. Further dilutions were made in sterile culture 188	
medium to achieve final concentrations of 0, 0.1, 1 and 10ng/ml in an initial dose-189	
response experiment. Thereafter, 5ng/ml TGF-β1 was selected as an optimal effective 190	
dose in further experiments. SB-431542 (Tocris Biosciences), a potent and selective 191	
inhibitor of TGF-β type I receptors ALK4, ALK5, and ALK7 (Vogt et al. 2011), was 192	
dissolved in ethanol to give a stock concentration of 10mM. Cells were treated with 193	
SB-431542 at final concentrations of 2µM and 10µM. Recombinant human BMP6 194	
(R&D Systems) was dissolved in sterile 4 mM HCl containing 0.1% bovine serum 195	
albumin to give a stock concentration of 20µg/ml. Further dilutions were made in 196	
sterile culture medium to achieve final BMP6 concentrations of 0, 1 and 5ng/ml. The 197	
selective inhibitor of BMP-responsive type 1 receptors (ALK1/2/6), K02288 (Tocris), 198	
was dissolved in ethanol to give a stock concentration of 10mM. K02288 specifically 199	
inhibits the BMP-induced Smad pathway without affecting TGF-β signaling 200	
(Sanvitale et al. 2013). Cells were treated with K02288 at final concentrations of 2µM 201	
and 10µM.  202	
 203	
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von Willebrand factor (vWF) immunostaining to identify endothelial cells 204	
At the end of culture, cells were fixed immediately and permeabilized in 205	
acetone:methanol (1:1) at 4℃ for 5 minutes then washed with PBS (3 x 5 minutes). 206	
To block endogenous peroxidase 3% (v/v) hydrogen peroxide in methanol was 207	
applied for 10 minutes at room temperature. Plates were washed in PBS buffer (3 x 5 208	
minutes), followed by serum blocking with 20% (v/v) normal goat serum for 30 209	
minutes at room temperature. Polyclonal rabbit anti-human vWF antibody (Dako, 210	
High Wycombe, UK) was used at 5µg/ml diluted in 2% (v/v) normal goat serum in 211	
PBS. A 200µl of the antibody solution was applied to each well and then incubated in 212	
a humidifier box for overnight at 4℃. On the second day, plates were washed in PBS 213	
(3 x 5 minutes). The primary antibodies were detected using the ABC Elite (Vector 214	
Laboratories, Peterborough, UK) method as follows: biotinylated secondary goat ant-215	
rabbit antibody was diluted 1:250 with 2% (v/v) normal goat serum in PBS and 216	
incubated for 30 minutes at room temperature. Plates were then washed in PBS (3 x 5 217	
minutes). The avidin-biotin complex was then prepared according to manufacturer’s 218	
instructions and applied to each well. After that, plates were incubated for 30 minutes 219	
at room temperature followed by further washes in PBS (3 x 5 minutes). Visualisation 220	
of bound antibodies was determined using 3,3’-diaminobenzidine tetrahydrochloride 221	
(DAB). The DAB solution was prepared according to the manufacturer’s instructions 222	
and incubated for 2 minutes, after which, the reaction was stopped by washing the 223	
wells using distilled water. Plates were counterstained with haematoxylin for 20 224	
seconds, washed in tap water before being dehydrated through a series of alcohols 225	
(70% ethanol (v/v) 1 x 5 minutes), (90% ethanol  (v/v) 1 x 5 minutes and 100% 226	
ethanol (v/v) 2 x 5 minutes. Coverslips were placed in histoclear for (2 x 20 seconds), 227	
removed (with cells attached) from the 24-well plates and then mounted on slides 228	
using DPX mounting medium. Images of all sections were visualised under 5x 229	
objective lens and then captured using an inverted microscope (Zeiss A1 Inverted 230	
Epifluorescent Microscope) fitted with a digital camera (Nikon NIS Elements).  231	
 232	
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Image analysis of vWF immunostaining  233	
A quantification method was developed, based on a protocol previously used to 234	
quantify area of vWF staining in a luteal endothelial cell culture (Robinson et al. 235	
2008). All image analysis was performed using ImageJ 2.0.0. The areas of brown 236	
staining (vWF) were highlighted and only areas stained positively for vWF within 237	
endothelial cell clusters were recorded. This was repeated for a total of 25 fields of 238	
view across the whole coverslip. In each independent experiment two coverslips were 239	
examined for each treatment and from this the mean % area of vWF staining was 240	
recorded. 241	
 242	
Real-time PCR analysis 243	
Cultured cells were processed for total RNA isolation using Qiagen RNeasy mini kits 244	
and cDNA was synthesized from 0.5µg RNA using the AB high capacity cDNA 245	
synthesis kit (Fisher Scientific, UK) according to the manufacturer’s instructions.  246	
cDNA samples were used for real-time PCR analysis of the expression of NR5A1, 247	
STAR, CYP11A1, HSD3B1, CYP17A1, INSL3 and LHR,  using the primers listed 248	
elsewhere (Glister et al. 2013). β-actin (ACTB) was used for normalization of gene 249	
expression. qPCR reactions were carried out as described previously (Glister et al. 250	
2010) using QuantiTect SYBR Green mastermix (Qiagen) and an AB StepOne plus 251	
thermal cycler (Applied Biosystems). Relative transcript abundance was evaluated 252	
using the ∆∆Ct method (Livak & Schmittgen 2001), with ACTB as the initial 253	
normalization control. ACTB showed uniform expression levels (Ct value) amongst 254	
the different treatment groups. Expression levels for each transcript were re-255	
normalized to corresponding values in vehicle-treated control cells. 256	
	257	
Hormone immunoassays 258	
Androstenedione and progesterone concentrations in cell-conditioned media were 259	
determined by competitive ELISA as described previously (Glister et al. 2005, Glister 260	




The effects of the various treatments on endothelial network formation, hormone 264	
secretion and gene expression were evaluated by one- and/or two-way analysis of 265	
variance (ANOVA) as indicated in results. After one-way ANOVA, post-hoc pairwise 266	
comparisons amongst different TGF-β-related treatments were made by Fisher’s 267	
PLSD test. In order to reduce heterogeneity of variance, data were log-transformed 268	
prior to statistical analysis. qPCR results were analysed as ∆∆Ct values (i.e. log2) 269	
before being converted to fold difference values for graphical presentation using the 270	
formula 2(-∆∆Ct). Results are presented as means ± SEM of ≥ 3 independent batches of 271	
cultured cells, as specified in each figure legend.  272	
 273	
Results  274	
Effects of VEGFA and FGF2 on endothelial network formation 275	
Immuno-staining (brown) of endothelial cells using vWF as a marker, revealed that a 276	
number of networks had formed in each culture (Fig. 1). Each network had a central 277	
body of endothelial cells from which a number of branches had developed. These 278	
networks appeared to be at different stages of development, with varying size and 279	
degree of branching. Statistical analysis showed that there was enhanced formation of 280	
endothelial networks in response to co-treatment with VEGFA and FGF2 (hereafter 281	
referred to as V/F) at both 1 and 10ng/ml, as indicated by a ~5-fold increase in % area 282	
of vWF immuno-staining when comparing to basal level (P<0.0001) (see Fig. 1d). 283	
 284	
Effect of TGF-𝜷1 and ALK5 inhibitor (SB-431542) on endothelial network 285	
formation  286	
As above, treatment of cells with V/F alone enhanced endothelial network formation 287	
by ~4-fold compared to basal level (P<0.02) (Fig. 2). TGF-β1 dose-dependently 288	
reduced endothelial cell network formation by up to ~90% under both basal and V/F-289	
induced conditions (P=0.004) (Figure 2). As shown in fig. 3, treatment with TGF-β1 290	
and the ALK5 inhibitor (SB-431542), alone and in combination, promoted marked 291	
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differences in the extent of endothelial cell network formation. As observed in the 292	
previous experiment, TGF-β1 (5ng/ml) reduced network formation by ~90% under 293	
both basal and V/F-induced conditions. Furthermore, the ALK5 inhibitor at 2 and 294	
10µM significantly reversed the inhibitory effect of TGF-β1 on network formation 295	
under both basal and V/F induced conditions. 296	
 297	
Effect of BMP6 and ALK1/2 inhibitor (K02288) on endothelial network 298	
formation  299	
As in previous experiments, V/F significantly increased endothelial network 300	
formation in comparison to basal level (P<0.001) (Fig. 4). Treatment with BMP6 301	
decreased V/F-induced endothelial cell network formation by up to ~70% (P<0.01) 302	
but did not affect network formation under basal conditions. Fig. 5 shows that Co-303	
treatment with the BMP inhibitor (K02288) reversed the suppressive action of BMP6 304	
observed under V/F-induced conditions. Moreover, under basal conditions, treatment 305	
with the BMP inhibitor alone, or in combination with BMP6, enhanced network 306	
formation ~4-fold. 307	
Effect of TGF-𝜷1 and ALK5 inhibitor (SB-431542) on progesterone and 308	
androstenedione secretion 309	
A significant (P<0.05) TGF-β1-induced decrease in progesterone production was 310	
observed under both basal and V/F-induced conditions. This suppressive action of 311	
TGF-β1was reversed by the TGF-β inhibitor (Fig. 6A).  Under basal conditions 312	
androstenedione concentrations in cell-conditioned media were very low,  ~1000-fold 313	
lower than progesterone concentrations and less than the assay detection limit in many 314	
samples. Treatment with TGF-β inhibitor alone induced a substantial (10 to100-fold; 315	
P<0.001) increase in androstenedione production under both basal and V/F induced 316	
conditions. This increase was reversed in cells co-treated with TGF-β1 (Fig. 6B). 317	
Two-way ANOVA showed that, overall, V/F treatment did not significantly affect 318	
secretion of either progesterone (P=0.33) or androstenedione (P=0.15). 319	
 320	
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Effects of TGF-β1 and ALK5 inhibitor on expression of steroidogenesis-related 321	
transcripts  322	
Fig. 7 shows the effects of TGF-β1 and its inhibitor on the relative expression of 323	
seven steroidogenesis-related transcripts by theca interna cells cultured under basal 324	
and V/F-stimulated conditions. Two-way ANOVA (not shown) indicated significant 325	
responses to TGF-β1 and its inhibitor for all seven transcripts examined (NR5A1, 326	
STAR, CYP11A1, HSD3B1, CYP17A1, INSL3, LHR) whereas V/F treatment had only 327	
a marginal effect on NR5A1 and INSL3 transcript abundance. Under basal conditions 328	
(without V/F) TGF-β1alone did not significantly affect levels of any transcript. 329	
However, the TGF-β inhibitor significantly (P<0.05) increased expression of all 330	
transcripts with the exception of NR5A1. These increases were reversed by TGF-β1 331	
co-treatment, significantly for all transcripts except CYP11A1 and LHR. Under V/F-332	
stimulated conditions, TGF-β1treatment alone significantly (P<0.05) decreased levels 333	
of CYP11A1, HSD3B1, CYP17A1 and LHR while co-treatment with TGF-β inhibitor 334	
reversed these effects. Treatment with the TGF-β inhibitor alone increased expression 335	
of NR5A1, STAR, HSD3B1, CYP17A1 and INSL3 (P<0.05). 336	
 337	
Effect of BMP6 and ALK1/2 inhibitor (K02288) on progesterone and 338	
androstenedione secretion 339	
Fig. 8A shows that under both basal and V/F induced conditions BMP6 reduced 340	
progesterone secretion by ~3-fold. Treatment with 10µM BMP6 inhibitor alone 341	
greatly increased (20 to 50-fold) progesterone secretion while co-treatment with 342	
BMP6 abolished this increase.  Fig. 8B shows a substantial (~100-fold) increase in 343	
androstenedione production in cells treated with 10µM of BMP6 inhibitor alone. This 344	
increase was reversed in cells co-treated with BMP6, under both basal and V/F-345	
induced conditions. BMP6 alone tended to reduce androstenedione secretion but the 346	
effect was not significant.  Two-way ANOVA showed that, overall, V/F treatment did 347	




Fig. 9 shows the effects of BMP6 and its inhibitor on the relative expression of seven 351	
steroidogenesis-related transcripts by theca interna cells cultured under basal and V/F-352	
stimulated conditions. Two-way ANOVA (not shown) indicated that V/F treatment 353	
had no overall effect on expression levels of any of the seven transcripts (P > 0.3). 354	
Under basal conditions (without V/F) BMP6 significantly reduced the abundance of 355	
INSL3 and LHR mRNA. However, the BMP inhibitor significantly (P<0.05) 356	
increased expression of STAR and CYP11A1 and tended to increase levels of the 357	
other five transcripts. In all cases except LHR these numerical increases were 358	
reversed (P<0.05) by BMP6 co-treatment. Under V/F-stimulated conditions, BMP6 359	
treatment alone significantly (P<0.05) decreased CYP11A1 expression, an effect 360	
reversed by co-treatment with the BMP inhibitor. In addition, treatment with the BMP 361	
inhibitor alone increased (P<0.05) the abundance of all seven transcripts and each 362	





During ovarian follicle development in vivo, follicular angiogenesis takes place 368	
concurrently with steroidogenesis. After ovulation, both processes resume in an 369	
intensive manner during follicle luteinization and CL formation (Wulff et al. 2001, 370	
Fraser et al. 2004, Berisha et al. 2016). During subsequent CL regression, initiated by 371	
the luteolytic action of uterine prostaglandin F2α (PGF2α) in ruminants, degeneration 372	
of the vascular bed is accompanied by a sharp decline in progesterone secretion.  373	
This study utilized a primary bovine theca interna cell culture model to generate novel 374	
information on the modulatory actions on angiogenesis and steroidogenesis of two 375	
TGF-β superfamily ligands known to be expressed at the intrafollicular level (TGF-β1, 376	
BMP6). Both ligands were shown to suppress ‘basal’ and/or VEGFA/FGF2-induced 377	
angiogenesis and steroidogenesis while pharmacological inhibitors of TGF-β 378	
signaling via ALK5 and BMP signaling via ALK1/2 reversed these effects. Both 379	
inhibitors also upregulated androstenedione secretion and expression of key 380	
steroidogenesis-related genes, including CYP17A1. 381	
	 14	
The ability of endothelial cells from the theca interna layer of follicles to re-assemble, 382	
proliferate and form capillary-like networks in vitro was demonstrated using a model 383	
system in which collagenase-digested theca interna tissue, containing both 384	
steroidogenic cells and vascular endothelial cells, was seeded on to gelatin-coated 385	
coverslips. To promote endothelial cell network formation, a commercial endothelial 386	
cell growth medium supplemented with various proprietary factors was utilized. In 387	
agreement with previous findings based on early bovine CL (Robinson et al. 2008, 388	
Woad et al. 2009) we demonstrated a robust increase in the formation of capillary-like 389	
networks in response to co-treatment with two well established angiogenic growth 390	
factors, VEGFA and FGF2. Despite this marked angiogenic response, VEGFA/FGF2 391	
co-treatment had little or no effect on steroidogenesis in this model, as reflected by 392	
secretion of progesterone and androstenedione or expression levels of key genes 393	
involved in the steroidogenic pathway. This suggests that the steroidogenic cells of 394	
the theca interna layer may lack responsiveness to VEGFA and/or FGF2, at least 395	
under the culture conditions used here.  Endothelial cells from bovine CL express 396	
FGFR, VEGFR1 and VEGFR2 (Gabler et al. 2004) but whether steroidogenic cells of 397	
the follicular theca interna also express these receptors remains to be established. Co-398	
localization studies using immunohistochemistry and/or in situ hybridization could 399	
address this issue. 400	
Whilst it is recognised that TGF-β can exert a dual role to either enhance or suppress 401	
different aspects of vasculogenesis and angiogenesis (Pepper et al. 1993, Orlova et al. 402	
2011, Mustafa et al. 2012, Guerrero & McCarty 2017), our data for bovine theca 403	
interna clearly showed that TGF-β1 induced a dose dependant inhibition of basal and 404	
VEGFA/FGF2-induced endothelial network formation. This action was reversed by a 405	
selective ALK5 inhibitor, indicating the likely pathway through which TGF-β signals 406	
in this context.  407	
In agreement with our findings, an inhibitory effect of TGF-β1 on bovine luteal 408	
endothelial cell function and capillary morphogenesis has also been reported (Maroni 409	
& Davis 2011). Since the uterine luteolytic signal PGF2α upregulates luteal 410	
expression of TGF-β the authors proposed a role for TGF-β in the luteolytic 411	
mechanism in ruminants (Maroni & Davis 2011). Indeed, this would be consistent 412	
with the TGF-β-induced reduction in thecal progesterone secretion observed in the 413	
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present study. TGF-β has also been shown to inhibit progesterone secretion by sheep 414	
granulosa cells (Juengel et al. 2004). Our findings also concur with a recent study 415	
showing that TGF-β1 dose dependently inhibited endothelial cell network formation 416	
in a BAEC culture model (Jarad et al. 2017). Additionally, the latter study showed 417	
that the inhibitory effect of TGF-β1 was accompanied by upregulation of the TGF-β 418	
accessory receptor endoglin, and Smad2 phosphorylation, but without affecting 419	
Smad1/5 phosphorylation. Moreover, TGF-β down regulated VEGFR2 level on the 420	
cell surface with a concomitant increase in secreted VEGFR2 level in endothelial cell-421	
conditioned medium, suggesting that the inhibitory action of TGF-β may involve a 422	
reduction in VEGFA signalling (Jarad et al. 2017). Further work would be required to 423	
determine if these considerations apply to the current theca interna culture model. It is 424	
also known that TGF-β family members can function in a paracrine manner to 425	
activate the production of pro-angiogenic cytokines, including VEGFA, TGF-𝛼 and 426	
monocyte chemo-attractant protein-1 (MCP1) (Vinals & Pouyssegur 2001, Deckers et 427	
al. 2002, Ma et al. 2007, Kuo et al. 2011, Guerrero & McCarty 2017). Additionally, 428	
TGF-β family members may modulate the function of other factors such as switching 429	
VEGFA from a pro-survival factor into a pro-apoptotic factor for endothelial cells 430	
(Ferrari et al. 2006, ten Dijke & Arthur 2007). 431	
Various BMPs, including BMP6 studied here, are expressed in the ovary and are 432	
recognised as autocrine/paracrine regulators of follicular and luteal cell proliferation 433	
and steroidogenesis (Elvin et al. 1999, Shimasaki et al. 2004, Knight & Glister 2006, 434	
Kayani et al. 2009). To our knowledge, the potential intraovarian role of BMPs on 435	
follicular or luteal angiogenesis has received little attention. However, BMP7 was 436	
reported to enhance VEGFA expression by human granulosa-lutein cells (Akiyama et 437	
al. 2014). Moreover, BMP6 and other related family members are expressed by 438	
vascular system cells including endothelial cells and smooth muscle cells suggesting 439	
autocrine or paracrine actions on the endothelium (Valdimarsdottir et al. 2002). 440	
Indeed, BMP6 was suggested to stimulate migration and tube formation of BAECs 441	
(Valdimarsdottir et al. 2002). In addition, BMP6 induced the proliferation and 442	
migration of mouse embryonic endothelial cells, as well as network formation and 443	
micro-vessel development in aortic rings (Ren et al. 2007, David et al. 2009). BMP2 444	
and BMP4 have also been shown to promote angiogenesis by stimulating the 445	
secretion of pro-angiogenic growth factors, including VEGFA (Kozawa et al. 2001, 446	
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Deckers et al. 2002). 447	
At variance with these reports, we found that BMP6 reduced VEGFA/FGF2-induced 448	
endothelial network formation in our bovine theca interna model, while the selective 449	
ALK1/2 inhibitor (K02288) reversed this effect. Moreover, K02288 alone enhanced 450	
network formation suggesting blockade of an inhibitory effect of endogenous BMP(s) 451	
signaling via ALK1/2. In contrast, we found that the ALK5 inhibitor alone did not 452	
enhance network formation above control levels, suggesting an absence of 453	
endogenous TGF-β ‘tone’ suppressing angiogenesis in this model. Since we have 454	
found endogenous expression of TGF-β1, 2 and 3 mRNA in this culture model (data 455	
not shown), this is somewhat surprising. It is possible that TGF-β mRNA is not 456	
translated or that post-translational processing does not generate bioactive ligand. 457	
Alternatively, binding protein(s) and/or coreceptors (betaglycan, endoglin) may 458	
modulate binding to signalling receptors (Castonguay et al. 2011). Another possible 459	
explanation is that the anti-angiogenic effect of endogenous TGF-β is mediated, at 460	
least in part, via a different ALK-Smad pathway in endothelial cells. In this context, 461	
evidence suggests that TGF-β can also signal via the ALK1/2-Smad1/5 pathway in 462	
endothelial cells (Goumans et al. 2002, Goumans et al. 2003). However, whilst TGF-463	
β signalling via ALK5 elicites an anti-angiogenic response, consistent with our 464	
findings in bovine theca interna cells, TGF-β signalling via ALK1/2 evidently 465	
enhances angiogenesis in other models (Oh et al. 2000, Shao et al. 2009, Orlova et al. 466	
2011). Evidence for ‘cross talk’ between ALK5 and ALk1/2-mediated signalling 467	
pathways has also been presented for other endothelial cell models, highlighting the 468	
complexity of potential regulatory mechanisms governing TGF-β signalling 469	
(Goumans et al. 2003, Orlova et al. 2011). 470	
Our finding that TGF-β and BMP6 elicited similar inhibitory effects on endothelial 471	
cell network formation under VEGFA-FGF2-stimulated conditions was unexpected 472	
given that they are purported to signal via different type1 receptor-Smad pathways, 473	
ALK5-Smad2/3 and ALK1/2-Smad1/5, respectively. However, this was reinforced by 474	
the observed ability of the ALK5 and ALK1/2 inhibitors to reverse, respectively, the 475	
anti-angiogenic actions of TGF-β and BMP6.  Moreover, BMP6 clearly suppressed 476	
basal and/or VEGFA/FGF2-induced progesterone secretion and expression of several 477	
key steroidogenesis-related genes. This observation is consistent with a previous in 478	
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vitro study on bovine theca-lutein cells (Kayani et al. 2009). The ability of the 479	
ALK1/2 inhibitor to reverse the inhibitory effect of BMP6 on progesterone production 480	
indicates that the response is likely mediated by the ALK1/2 pathway. However, as 481	
observed for the angiogenic response, treatment with the ALK1/2 inhibitor alone 482	
promoted substantial increases in secretion of progesterone and androstenedione, 483	
accompanied by increased expression of most of the steroidogenesis-related genes 484	
examined. As such, these observations reinforce the view that endogenous BMPs 485	
expressed by the cultured cells exert a dual suppressive action on both angiogenesis 486	
and steroidogenesis. Interestingly, luteal expression of several BMPs, including 487	
BMP6, increases during the late luteal phase in bovine (Kayani et al. 2009) and 488	
human (Nio-Kobayashi et al. 2015) consistent with their involvement in luteolysis. 489	
Moreover, BMP expression by human granulosa-lutein cells was downregulated by 490	
human chorionic gonadotrophin, reinforcing this concept (Nio-Kobayashi et al. 2015). 491	
Regarding the gene expression analyses, neither total RNA yield, nor expression 492	
levels of the normalization control gene (ACTB) were affected by any of the 493	
treatments (data not shown). However, it is possible that the observed changes in 494	
relative expression levels of steroidogenesis-related genes in our culture model could 495	
be due, at least in part, to treatment-induced changes in relative numbers of different 496	
cell-types contributing to the total RNA extracted from cell lysates at the end of 497	
culture.  498	
It should be noted that culture conditions influence the extent to which follicular theca 499	
interna cells undergo luteinisation in vitro, as reflected by their morphological 500	
phenotype, transcriptional profile and steroid secretory profile (i.e. progesterone to 501	
androstenedione ratio) (Campbell et al. 1998, Glister et al. 2005, Kayani et al. 2009). 502	
In general, exposure to serum-supplemented media and/or high concentrations of LH, 503	
forskolin or insulin promotes luteinisation, accompanied by a substantial increase in 504	
progesterone to androstenedione ratio. The culture conditions used in the present 505	
endothelial cell culture model (including use of serum-supplemented medium for first 506	
day of culture) would be expected to induce some degree of cellular luteinisation. 507	
Indeed, the cells formed an adherent monolayer and the progesterone to 508	
androstenedione ratio in cell-conditioned medium was very high (>100:1) under all 509	
treatment conditions. This contrasts with the progesterone to androstenedione ratio of 510	
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~2:1exhibited by ‘non-luteinised’ bovine theca interna cells cultured under defined, 511	
serum-free conditions (Glister et al. 2005). The challenge remains to devise a 512	
follicular theca interna angiogenesis culture model that mimics more closely the 513	
physiological status of a healthy growing follicle, rather than a luteinizing follicle. 514	
In conclusion, the present results indicate that both TGF-β1 and BMP6 exert 515	
inhibitory actions on ovarian angiogenesis and steroidogenesis, likely mediated by 516	
ALK5 and ALK1/2 signalling pathways. Further experiments, beyond the scope of 517	
the present study, are needed to unravel the complex interactions between multiple 518	
TGF-β superfamily ligands and other regulatory factors implicated in the dual control 519	
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Fig. 1 Development of endothelial cell network in theca interna culture system in 541	
response to co-treatment with VEGFA and FGF2 (V/F). Endothelial cells were 542	
immuno-stained brown with vWF antibody as shown in representative images of (A) 543	
control cells; (B) cells treated with 1ng/ml V/F; (C) cells treated with 10ng/ml V/F; 544	
(D) % area of vWF immunostaining based on quantitative analysis of images from 5 545	
independent cultures. Values are means and bars indicate SEM. ***P<0.001 versus 546	
controls. Scale bars indicate 100 µm. 547	
	548	
Fig. 2 The effect of TGF-𝛽1 alone and in combination with VEGFA and FGF2 (V/F) 549	
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indicate SEM (n=3 independent batches of cells); two-way ANOVA results are 551	
shown.  552	
	553	
Fig. 3A Effect of TGF-𝛽1 and the ALK5 inhibitor (SB-431542), alone and in 554	
combination, on basal and VEGFA/FGF (V/F)-induced network formation in cultured 555	
theca interna cells. Values are means and error bars indicate SEM (n=5 independent 556	
batches of cells). Separate one-way ANOVA and post-hoc pairwise comparisons were 557	
made for cells cultured with and without V/F; means without a common letter are 558	
significantly different (P < 0.05). B shows representative images of cells treated with 559	
vehicle, TGF-𝛽1and SB-431542 (2𝜇𝑀) in the presence and absence of V/F. Scale 560	
bars = 100 µm. 561	
Fig. 2 
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	562	
Fig. 4 Effect of BMP6 in the presence/absence of VEGFA and FGF2 (V/F) on 563	
network formation by cultured theca interna cells. Values are means and error bars 564	
indicate SEM (n=3 independent batches of cells); two-way ANOVA results are 565	
shown. 566	
Fig. 3  
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Fig. 5A Effect of BMP6 and BMP inhibitor (K02288), alone and in combination, on 568	
basal and VEGFA/FGF2 (V/F)-induced network formation in cultured theca interna 569	
cells. Values are means and error bars indicate SEM (n=5 independent batches of 570	
cells). Separate one-way ANOVA and post-hoc pairwise comparisons were made for 571	
cells cultured with and without V/F; means without a common letter are significantly 572	
different (P < 0.05). B shows representative images of cells treated with vehicle, 573	









































BMP6  P = 0.01    
V/F  P < 0.001 
BMP6 x V/F  P = 0.01 
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	575	
Fig. 6 The effect of TGF-β1 and its antagonist alone or in combination on basal and 576	
VEGFA/FGF2 (V/F)-induced production of (A) progesterone and (B) 577	
androstenedione by cultured bovine theca interna cells. Values are means and bars 578	
indicate SEM (n=5 independent batches of cells). Separate one-way ANOVA and 579	
post-hoc pairwise comparisons were made for cells cultured with and without V/F; 580	
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Fig. 7 Changes in relative expression of steroidogenesis-related mRNA transcripts in 583	
cultured theca interna cells treated with TGF-𝛽1 and its inhibitor (SB-431542) alone 584	
and in combination, under ‘basal’ (open bars) and V/F-stimulated (filled bars) 585	
conditions: (A) NR5A1; (B) STAR; (C) CYP11A1; (D) HSD3B1; (E) CYP17A1; (F) 586	
INSL3; (G) LHR. Values are means and bars indicate SEM (n=5 independent batches 587	
of cells) Results of one-way ANOVA and post-hoc pairwise comparisons are 588	
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	590	
Fig. 8 Effect of BMP6 and its antagonist alone or in combination in the 591	
presence/absence of VEGFA and FGF2 (V/F), on the production of (A) progesterone 592	
and (B) androstenedione by bovine theca layer cultured cells. Values are means and 593	
bars indicate SEM (n=5 independent batches of cells). Separate one-way ANOVA 594	
and post-hoc pairwise comparisons were made for cells cultured with and without 595	
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	597	
Fig. 9 Changes in relative expression of steroidogenesis-related mRNA transcripts in 598	
cultured theca interna cells treated with BMP6 and the ALK1/2 inhibitor (K02288) 599	
alone and in combination, under ‘basal’ (open bars) and V/F-stimulated (filled bars) 600	
conditions. (A) NR5A1; (B) STAR; (C) CYP11A1; (D) HSD3B1; (E) CYP17A1; (F) 601	
INSL3; (G) LHR. Values are means and bars indicate SEM (n=5 independent batches 602	
of cells) Results of one-way ANOVA and post-hoc pairwise comparisons are 603	
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